DeSci has proven it can fund real science.
The next bottleneck is adoption: attention → onboarding → retention → revenue.
Being a pharmacist + Web3 Growth/BD operator with 8yrs experience and $3.5M in sales, I know a thing or two about generating revenue.
I help DeSci projects fix onboarding, incentives, and community quality.
If you’re building in DeSci and want adoption (not token hunters/mercenaries), DM me.
The new AxonDAO Grant Program is here.
We’re opening support for researchers and teams building in health AI, DeSci, bioinformatics, and scientific computing.
Selected applicants can access funding, compute credits, mentorship, and industry connections to help advance their work.
If your research needs infrastructure, guidance, or access, start here:
https://t.co/Tr9DToAnCE
We’re going live in 1 hour.
Chris (CEO)@Chris_AxonDAO, Dr. Avi (CTO)@iAvimanyu and Christian (CMO)@OnChainChris will be live at 2PM UTC for today’s AxonDAO team Space.
If you’ve been trying to understand where AxonDAO is heading next, this is the one to join.
We’ll talk through the new site, the ecosystem story behind it, the new drop coming this week, and questions from the community.
Drop your question before we go live. One eligible question answered during the Space will be randomly selected to win 10,000 AXGT.
Join here:
https://t.co/YbvLjlWOrC
Axonians, tomorrow is a big one.
Join Chris (CEO)@Chris_AxonDAO, Dr. Avi (CTO) @iAvimanyu, and Christian (CMO) @OnChainChris for a team Space at 2PM UTC.
We’ll be talking through the new AxonDAO site, what it means for the ecosystem, and a new drop coming this week.
We’re also pulling questions directly from the comments for a live Q&A.
Ask your question below.
One question answered during the Space will be randomly selected to win 10,000 AXGT.
Set a reminder:
https://t.co/YbvLjlWgC4
We've crossed $50,000 in GPU revenue through AxonGPU 🫡
You can always check out the most recent live stats on our fleet by visiting: https://t.co/G8Qb247R8C
Axon Academy Ep 5 is live.
This one is all about the process of scientific discovery. What used to be years in the lab has now turned into days or weeks of compute usage.
Scientific discovery as we know it is changing, and AxonOS is positioned to support the next generation of scientific researchers.
Three Common Cancers affecting Nigerians and how you can prevent them. Please share with others.
Get screening and immediate review of your tests with a healthcare professional using @BookclinicN
Despite Nigeria’s abundant sunshine, i find it interesting that up to a third or more of the population suffers from low vitamin D levels.
This is primarily caused by darker skin pigmentation, which reduces UV absorption, paired with indoor urban lifestyles, cultural sun-avoidance, and diets lacking fortified foods.
I’d be interested in knowing to what extent low vitamin D levels causes hormonal imbalance in Nigerian women.
We just burned 1,000,000 $AXGT to celebrate the launch of our new website. The tokens used for the burn were purchased by AxonDAO using revenue from GPU rentals.
Proof: https://t.co/4OGsRWlU7x
MAJOR ANNOUNCEMENT ‼️
Cerebrum DAO has partnered with Waves – a browser-based brain health platform grounded in world-class neuroscience.
At the center is Celeste, an AI coach built on SMART (Strategic Memory Advanced Reasoning Tactics), a cognitive neuroscience methodology developed at the UT Dallas Center for BrainHealth:
→ 25+ years of peer-reviewed RCT evidence
→ Validated in 3,966 adults over 3 years
→ Published in Scientific Reports (Nature Portfolio), May 2026
It's time to https://t.co/OhAwxxVCn4
Hold AXGT? Your compute access may cost less.
When AxonOS access opens, eligible AXGT holders can reduce the ETH price they pay for compute.
Exact terms will be live when access opens.
Research often slows down before the workload even starts.
The researcher knows what needs to run.
The model, dataset, or pipeline may already be clear, and the compute may exist somewhere.
The hard part is getting from intent to execution.
By the time access is approved, environments are configured, dependencies are fixed, and payment or procurement is sorted, the team has already lost time before the first run begins.
AxonGPU and AxonOS help close that gap by giving research and AI teams a clearer path from workload to usable compute.
Scientific work should not get stuck at setup.
In our science AMA, we discussed the exciting area of brain lipid research and its connection to neurodegeneration.
We welcome proposals or ideas from any researchers with projects in this area. Since research is outstripping funding, this is the exact gap we seek to fill.
AxonOS helps you go from checkout to workload in minutes.
Choose your GPUs, pay with crypto, and open your AxonOS environment. No long onboarding process.
Launching soon.
Percepta is our flagship product at the Cognition store, but we're working on some new, exciting additions very soon.
Try Percepta for the first time and get 15% off with code CLAW15.
https://t.co/kh2PFDfHUj
Took a stab at designing orally available MOTS-C at this with @peptai_ - took our agents 150min
What is the problem? Native MOTS-c is rapidly destroyed by enzymes in the blood and gut, cannot cross cell membranes efficiently, and cannot be taken as a pill. These properties make it unsuitable as a drug in its natural form.
What did we do? Using an AI-assisted computational workflow, we designed 306 chemically modified versions of MOTS-c and ranked them by predicted stability, permeability, and preservation of the key residues believed to be responsible for CK2-alpha interaction. We identified 3 synthesis-priority candidates and produced a complete experimental plan to test them.
What did we NOT do?
We did not make or test any of these peptides. All
results are computational predictions. No peptide has been shown to bind CK2-alpha, activate the enzyme, survive in blood, cross a membrane, or treat any disease. These are experimentally testable hypotheses, not validated therapeutics.
What happens next? The recommended next step is to synthesize 11 peptides (3 designed analogues + 8 controls) and run 3 laboratory assays: a binding test, an enzyme activation test, and a stability test. Estimated cost: USD 35,000–60,000.
Estimated timeline: 10–14 weeks.
Happy to share the full paper or some of the candidates, I agree with @BasedBiohacker though the IP here could be really valuable
Incredible opportunity working at the forefront of AI for science + peptide R&D
Please share in your local university networks
$2500 referral fee 🧪
Scientists have reportedly managed to make old human skin cells behave like much younger ones, in some cases appearing biologically around 30 years younger.
Researchers used a process involving “Yamanaka factors,” a group of proteins that can partially reset a cell’s biological clock. Normally, exposing cells to these factors for too long turns them back into stem cells, which lose their original identity. Instead, the team stopped the process after about 13 days, long enough to rejuvenate the cells but short enough for them to remain skin cells.
The rejuvenated cells showed molecular patterns seen in younger cells, produced more collagen, and repaired wounds faster in laboratory tests. Scientists believe this could one day help treat age-related diseases or improve tissue repair, though the research is still in its early stages.
Credit: Gill, D., Parry, A., Santos, F., Okkenhaug, H., Todd, C. D., Hernando-Herraez, I., and Reik, W., Multi-omic rejuvenation of human cells by maturation phase transient reprogramming, eLife.